3000724
print

B-Lymphoblastic Leukemia (B-ALL) Minimum Residual Disease Detection by Flow Cytometry

B-ALL MRD
Example Reports
Negative COG
Negative
Positive COG
Positive

Icon

Time Sensitive

Icon

Additional Technical Information

Ordering Recommendation

Use to detect minimal residual disease (MRD) in patients of all ages previously diagnosed with B-ALL. The specific markers used and reported vary based on the specimen submitted and whether a Children's Oncology Group (COG) protocol is specified at the time of ordering. Orders for whole blood testing will be canceled if the patient is 18 years or older or if there is a prior history of COG whole blood testing. For more information, refer to Additional Technical Information.

New York DOH Approval Status

This test is not New York state approved. There are no New York state-approved laboratories available. Submit a Non-Permitted Laboratory Request Form (NPL) to the NYDOH prior to collection of specimen. If NPL is approved by NYDOH, and sample is received at ARUP, testing will be performed.

Specimen Required

Patient Preparation
Collect

Bone marrow. Whole blood: Green (sodium heparin) or lavender (EDTA).

Specimen Preparation

Transport 2 mL heparinized bone marrow (Min: 1.0 mL) OR 3 mL whole blood (Min: 1.0 mL)

Storage/Transport Temperature

Room temperature. Also acceptable: Refrigerated. Specimen should be received within 24 hours of collection for optimal cell viability.

Unacceptable Conditions

Clotted or hemolyzed specimens.

Remarks

Provide specimen source, CBC, Wright-stained smear (if available), clinical history, differential diagnosis.
Follow up: If previous leukemia/lymphoma phenotyping was performed at another lab, the outside flow cytometry report and histograms (if possible) should accompany the specimen.

Stability

Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable

Methodology

Flow Cytometry

Performed

Sun-Sat

Reported

1-3 days

Reference Interval

By Report

Interpretive Data

Refer to report.

Compliance Category

Analyte Specific Reagent (ASR)

Note

This assay is a minimal residual disease assessment of B-ALL by flow cytometry.

Available markers*: CD3, CD9, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD45, CD58, CD71, Syto 16, CD66b, CD24, CD22

*Not all markers will be reported in all cases.

If COG panel is not specified, a 10-marker panel will be run:
CD10, CD19, CD20, CD22, CD24, CD34, CD38, CD45, CD58, CD66b

If COG panel is specified, indicate time point and specimen type:

DAY 8 Peripheral blood sample will have CD10, CD19, CD20, CD34, CD45, and Syto 16 run and reported (6 markers total).

Day 29 Bone marrow sample will have CD3, CD9, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD45, CD58, CD71, Syto 16 run and reported (13 markers total).

The report will include a pathologist interpretation and a marker interpretation range corresponding to CPT codes of 2-8 markers or 9-15 markers interpreted. Charges apply per marker.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
08/21/2023
X
N/A

CPT Codes

88184; 88185 each additional marker; 88187 or 88188.

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
3000737 Number of Markers 19099-1
3000738 B-All MRD Interpretation 45267-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Acute Leukemia Follow up Phenotyping by Flow Cytometry
  • Follow-Up Phenotyping
  • Leukemia/Lymphoma Evaluation Panel
  • Leukemia/Lymphoma Phenotyping, Comprehensive - Miscellaneous
  • Leukemia/Lymphoma Phenotyping, Comprehensive - Whole Blood
  • Hematopoietic neoplasms monitoring
  • Leukemia/Lymphoma Phenotyping, Comprehensive - Bone Marrow
B-Lymphoblastic Leukemia (B-ALL) Minimum Residual Disease Detection by Flow Cytometry